Hiperemezis and Serotonin Elevated Serum Serotonin Levels in Hyperemesis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01987869|
Recruitment Status : Unknown
Verified November 2013 by Bakirkoy Dr. Sadi Konuk Research and Training Hospital.
Recruitment status was: Recruiting
First Posted : November 19, 2013
Last Update Posted : November 19, 2013
|Condition or disease|
|Nausea Vomiting Markedly Reduced Food Intake Severe Dehydration|
The occurrence of severe nausea and vomiting of early pregnancy (hiperemezis gravid arum) is estimated between 0.3% to 1% of all pregnancies. Although hiperemezis gravid arum has been recognized for a long time, its pathophysiologic mechanisms are still poorly understood. Many theories have been advocated, but to date none of these have been convincing.
It has been demonstrated that the nausea and vomiting associated with increased in serotonin liberation. This has provided a rationale for the treatment of these symptoms with specific serotonin antagonists.
The aim of this trial was to investigate the possible relationship between hiperemezis gravid arum and serotonin liberation.
|Study Type :||Observational|
|Estimated Enrollment :||90 participants|
|Official Title:||Relationship Between Elevated Serum Serotonin Levels in Symptomatic Patients With Hyperemezis|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||February 2014|
|Estimated Study Completion Date :||March 2014|
- serum serotonin levels in hiperemezis gravidarum [ Time Frame: 6-14week pregnancy ]
- ıs there any assosiation between serotonin levels and severity of symptoms in pregnant women with hiperemezis [ Time Frame: 6-14week pregnancy ]
- ıs there any assosiation between other serum parameters includes estrogen,progesterone and serum beta hcg [ Time Frame: 6-14week pregnancy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01987869
|Contact: hediye dağdeviren, email@example.com|
|Bakirkoy Dr Sadi Konuk Training and Research Hospital||Recruiting|
|Istanbul, Turkey, 34140|
|Contact: hediye dagdeviren, md 5079872463 firstname.lastname@example.org|
|Principal Investigator: huseyin cengiz, md|
|Study Chair:||hüseyin cengiz, md||Bakırkoy Dr. Sadi Konuk Training and Research Hospital|